Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study.

The Journal of antimicrobial chemotherapy - 1 Sept 2026

Sempere Abiu, de la Mora Lorena, Inciarte Alexy, Berrocal Leire, Gonzalez-Cordón Ana, Mosquera Cepeda María Mar, De Lazzari Elisa, Martinez Rebollar María, Laguno Montserrat, Torres Berta, Chivite Ivan, Callau Pilar, Calvo Julia, Ambrosioni Juan, Mallolas Josep, Foncillas Alberto, Miro José María, Rigo-Bonnin Raúl, Martínez Esteban, Blanco José Luis

Abstract excerpt

OBJECTIVES: The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs). METHODS: DorSwitch is a prospective pilot study including 13 adults with...

Read the complete abstract on PubMed

Topics

Humans
Pilot Projects
Nitriles
Triazoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

HIV Infections

Drug Resistance, Viral

Anti-HIV Agents

Female

HIV-1

Adult

Pyridones

Male

Prospective Studies

Pyrimidines

Middle Aged

Reverse Transcriptase Inhibitors

Drug Substitution

Darunavir

Source

Identifiers

PMID: 42695345
DOI: 10.1093/jac/dkag297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study.PMID 42695345Read ↗

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read ↗

Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.Semantic proximity Read ↗

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.Semantic proximity Read ↗

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.Semantic proximity Read ↗

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimensSemantic proximity Read ↗

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.Semantic proximity Read ↗

Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.Semantic proximity Read ↗

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.Semantic proximity Read ↗

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug ResistanceSemantic proximity Read ↗

Emerging reverse transcriptase inhibitors for HIV-1 infectionSemantic proximity Read ↗

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to DoravirineSemantic proximity Read ↗

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.